J. Llovet

J. Llovet, 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

L. Mariani, V. Mazzaferro, A. Burroughs, 2009, The Lancet. Oncology.

Major achievements in hepatocellular carcinoma

J. Bruix, J. Llovet, 2009, The Lancet.

The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma

Josep Fuster, J. Bruix, J. Llovet, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Percutaneous treatment for unresectable hepatocellular carcinoma. Predictors of long-term survival of 274 patients in a single institution

J. Bruix, J. Llovet, C. Ayuso, 2003 .

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

M. Kudo, P. Galle, G. Gerken, 2021, British Journal of Cancer.

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma

J. Llovet, S. Thung, M. Schwartz, 2009 .

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.

J. Llovet, 2014, Cancer cell.

MS.liverK: an R package for transcriptome-based computation of molecular subtypes and functional signatures in liver cancer

X. Wang, S. Thorgeirsson, J. Zucman‐Rossi, 2019, bioRxiv.

HCC surveillance: Who is the target population?

J. Bruix, J. Llovet, 2003, Hepatology.

Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.

S. Friedman, J. Llovet, E. Lemmer, 2006, Seminars in liver disease.

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

J. Llovet, D. Dieterich, A. Villanueva, 2020, Oncogene.

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

J. Llovet, R. Finn, 2018, The Lancet. Oncology.

Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".

J. Bruix, J. Llovet, Ann Lii Cheng, 2017, Journal of hepatology.

Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".

R. Lencioni, J. Llovet, R. Montal, 2017, Journal of hepatology.

Reply to X. Qi et al.

J. Llovet, P. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib and the benefits of a negative study.

J. Bruix, J. Llovet, A. Forner, 2009, The Lancet. Oncology.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

S. Friedman, J. Llovet, Clara Alsinet, 2012, Journal of hepatology.

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

J. Bruix, J. Llovet, P. Ruff, 2001, European journal of cancer.

Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound.

J. Llovet, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

2 Hepatitis C virus (HCV) recurrence is an early and severe event in living donor liver transplantation (LDLT)

J. Llovet, M. Navasa, J. Fuster, 2004 .

Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study.

J. Bruix, J. Llovet, L. Grande, 2004, Hepato-gastroenterology.

For the EASL Panel of Experts on hepatocellular carcinoma

A. Burroughs, J. Bruix, M. Sherman, 2001 .

Carcinogen‐induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation

S. Friedman, J. Llovet, M. Oren, 2011, Hepatology.

Molecular Oncology: Hepatocellular carcinoma

Derek Y. Chiang, J. Llovet, Y. Hoshida, 2013 .

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications

R. Schwabe, V. Mazzaferro, S. Friedman, 2022, Gut.

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC

J. Llovet, D. Sia, R. Pinyol, 2019, Clinical Cancer Research.

class predicts resistance to 2 immunotherapies in HCC 3

J. Llovet, D. Sia, R. Pinyol, 2019 .

Contralateral trigeminal neuralgia as a false localizing sign in intracranial tumors.

J. Llovet, A. Pou, R. Florensa, 1987, Neurosurgery.

[Tethered cord syndrome with intradural sacral lipoma in an adult male].

J. Llovet, R. Estruch, J. Casademont, 1984, Medicina clínica (Ed. impresa).

[Hemangioblastoma of the spinal cord. A case with a probably single lesion (author's transl)].

J. Llovet, A. Pou-Serradell, R. Florensa, 1981, Revue neurologique (Paris).

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

R. Schwabe, B. Stockwell, A. Califano, 2021, Cancer cell.

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Ramon Planas, Carmen Ayuso, J. Bruix, 2002, The Lancet.

Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization.

J. Bruix, J. Llovet, 2004, Radiology.

Expected developments in hepatology.

J. Bruix, J. Llovet, X. Forns, 2002, Best practice & research. Clinical gastroenterology.

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Caroline L. Wilson, Patrick M. Helbling, F. Tacke, 2019, Nature Network Boston.

Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase 3 Randomized, Placebo-Controlled Trial

J. Llovet, C. Helwick, 2007 .

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

Arthur Liberzon, Masahiro Kobayashi, Yujin Hoshida, 2011, Gastroenterology.

Reply to: ''Network-based discovery of gene signature for vascular invasion prediction in HCC''

J. Llovet, D. Sia, B. Mínguez, 2012 .

1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

Masatoshi Kudo, Yoon-Koo Kang, Won Young Tak, 2012 .

Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.

J. Bruix, R. Lencioni, J. Llovet, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

J. Bruix, J. Llovet, Jordi Bruix, 2003, Hepatology.

Emerging agents for the medical therapy of hepatocellular carcinoma.

J. Llovet, 2007, Gastroenterology & hepatology.

Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial

C. Porta, J. Bruix, J. Llovet, 2008 .

67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE

J. Bruix, M. Sherman, J. Llovet, 2009 .

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2

M. Kudo, P. Galle, G. Brandi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein.

M. Kudo, P. Galle, J. Llovet, 2019, The Lancet. Oncology.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

M. Kudo, J. Bruix, M. Sherman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and predictors of sorafenib beneﬁt in patients with hepatocellular carcinoma: Analysis of two phase III studies

J. Bruix, J. Llovet, A. Cheng, 2017 .

Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020).

J. Llovet, A. Villanueva, M. Schwartz, 2021, Gastroenterology.

Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma

J. Llovet, Judit Peix, C. Montironi, 2020, Journal of Hepatology.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Schirmacher, J. Llovet, B. Sangro, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.

M. Kudo, P. Galle, G. Gerken, 2019, Journal of Clinical Oncology.

Hepatocellular carcinoma enters the sequencing era.

J. Llovet, Y. Hoshida, A. Villanueva, 2011, Gastroenterology.

Intratumoral heterogeneity and clonal evolution in liver cancer

Gustavo Stolovitzky, Eric E. Schadt, Bojan Losic, 2020, Nature Communications.

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Rameen Beroukhim, Brandy Klotzle, Barbara Tabak, 2013, Gastroenterology.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era

J. Llovet, R. Finn, A. Villanueva, 2015, Nature Reviews Clinical Oncology.

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

V. Mazzaferro, J. Llovet, N. Bardeesy, 2015, Clinical Cancer Research.

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

Llorenç Quintó, Xavier Forns, J. Llovet, 2002, Hepatology.

Resection and Liver Transplantation for Hepatocellular Carcinoma

V. Mazzaferro, J. Llovet, M. Schwartz, 2005, Seminars in liver disease.

Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.

J. Llovet, J. Emond, B. Samstein, 2022, JAMA surgery.

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

M. Kudo, P. Galle, S. Kaneko, 2019, Journal of Clinical Oncology.

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

X. Wang, G. Gores, J. Llovet, 2022, Nature Cancer.

Milestones in the pathogenesis and management of primary liver cancer.

Bruno Sangro, J. Llovet, B. Sangro, 2020, Journal of hepatology.

Smoking, hepatitis B virus infection, and development of hepatocellular carcinoma.

M. Sherman, J. Llovet, 2011, Journal of the National Cancer Institute.

Hepatocellular carcinoma: a clinical update.

J. Llovet, Fernando Pons-Renedo, 2003, MedGenMed : Medscape general medicine.

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

J. Bruix, J. Llovet, A. Castells, 1998, Hepatology.

Nonsurgical treatment of hepatocellular carcinoma

J. Bruix, J. Llovet, M. Sala, 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[Acute spontaneous subdural hematoma of arterial origin].

J. Llovet, F. Pujadas, C. Ricart, 1986, Neurologia.

HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management

J. Llovet, S. Toffanin, H. Cornellà, 2012, Hepatology.

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.

J. Llovet, M. Navasa, V. Arroyo, 1996, Gastroenterology.

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

J. Llovet, M. Navasa, V. Arroyo, 1996 .

Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study.

J. Llovet, E. Cabré, M. Gassull, 1993, The American journal of gastroenterology.

Two decades of advances in hepatocellular carcinoma research.

J. Bruix, J. Llovet, 2010, Seminars in liver disease.

Next-generation sequencing: path for driver discovery in hepatocellular carcinoma.

J. Llovet, S. Toffanin, H. Cornellà, 2012, Gastroenterology.

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH).

P. Galle, J. Llovet, A. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma

J. Llovet, Philipp K. Haber, Catherine E. Willoughby, 2021, Clinical Cancer Research.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial

D. Amadori, V. Mazzaferro, J. Bruix, 2008 .

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH).

P. Galle, J. Llovet, A. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.

M. Kudo, K. Ueshima, R. Lencioni, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment

J. Llovet, D. Madoff, R. Finn, 2020 .

STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)

M. Makuuchi, V. Mazzaferro, M. Kudo, 2014 .

RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).

M. Kudo, J. Bruix, J. Llovet, 2014 .

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

M. Kudo, P. Galle, K. Rau, 2020, Zeitschrift für Gastroenterologie.

Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)

M. Kudo, P. Galle, G. Brandi, 2019, Annals of Oncology.

Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

M. Kudo, T. Berg, P. Galle, 2019, Annals of Oncology.

Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study.

K. Knešaurek, J. Llovet, M. Schwartz, 2022, The lancet. Gastroenterology & hepatology.

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

J. Bruix, J. Llovet, A. Forner, 2007, Hepatology.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial

J. Marrero, J. Bruix, J. Llovet, 2008 .

3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma

V. Mazzaferro, S. Ricci, J. Llovet, 2007 .

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

V. Mazzaferro, J. Barretina, S. Friedman, 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

R. Schwabe, B. Stockwell, A. Califano, 2021, Cancer cell.

DNA Methylation Profiling of Human Hepatocarcinogenesis

M. Esteller, V. Mazzaferro, J. Llovet, 2020, Hepatology.

A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.

J. Llovet, S. Thung, M. Schwartz, 2009, Gastroenterology.

Novel advancements in the management of hepatocellular carcinoma in 2008.

J. Bruix, J. Llovet, 2008, Journal of hepatology.

Liver transplantation in hepatocellular carcinoma

J. Bruix, J. Llovet, J. Fuster, 2005, Transplant international : official journal of the European Society for Organ Transplantation.

The current status of liver transplantation for primary hepatic malignancy.

J. Bruix, J. Llovet, J. Fuster, 2000, Clinics in liver disease.

Locoregional treatments for hepatocellular carcinoma.

J. Bruix, J. Llovet, 1999, Bailliere's best practice & research. Clinical gastroenterology.

Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

J. Bruix, J. Llovet, J. Fuster, 1999, Hepatology.

[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH].

J. Bruix, J. Llovet, A. Forner, 2016, Medicina clinica.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Kenji Ikeda, Derek Y. Chiang, Goro Watanabe, 2008, The New England journal of medicine.

New aspects of diagnosis and therapy of hepatocellular carcinoma

J. Bruix, J. Llovet, A. Forner, 2006, Oncogene.

Updated treatment approach to hepatocellular carcinoma

J. Llovet, Josep M. Llovet, 2005, Journal of Gastroenterology.

Treatment of hepatocellular carcinoma

J. Llovet, 2004, Current treatment options in gastroenterology.

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation

J. Bruix, J. Llovet, M. Navasa, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Treatment of hepatocellular carcinoma: is there an optimal strategy?

J. Bruix, J. Llovet, M. Varela, 2003, Cancer Treatment Reviews.

Hepatocellular carcinoma: present status and future prospects.

J. Llovet, M. Beaugrand, 2003, Journal of hepatology.

Evidence‐based medicine in the treatment of hepatocellular carcinoma

J. Llovet, 2002, Journal of gastroenterology and hepatology.

Interferon for the prevention of hepatocellular carcinoma

J. Bruix, J. Llovet, M. Sala, 2002 .

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

L Pagliaro, A. Burroughs, J. Bruix, 2001, Journal of hepatology.

Special article Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

A. Burroughs, J. Bruix, M. Sherman, 2001 .

Early diagnosis and treatment of hepatocellular carcinoma.

J. Bruix, J. Llovet, 2000, Bailliere's best practice & research. Clinical gastroenterology.

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

G. Gores, J. Bruix, J. Llovet, 2000, Hepatology.

Diagnosis and treatment of hepatocellular carcinoma.

J. Bruix, J. Llovet, M. Sala, 1999, Acta gastro-enterologica Belgica.

Liver cancer: Time to evolve trial design after everolimus failure

J. Llovet, 2014, Nature Reviews Clinical Oncology.

Molecular therapies and precision medicine for hepatocellular carcinoma

J. Llovet, R. Finn, D. Sia, 2018, Nature Reviews Clinical Oncology.

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

M. Kudo, M. Sherman, P. Galle, 2019, Liver international : official journal of the International Association for the Study of the Liver.

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.

J. Marrero, A. Lok, M. Sherman, 2021, Gastroenterology.

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

V. Mazzaferro, L. Bassaganyas, J. Bruix, 2018, Gut.

Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.

J. Llovet, I. Ojanguren, E. Cabré, 1994, Gut.

Experimental models of hepatocellular carcinoma.

S. Friedman, J. Llovet, K. Koike, 2008, Journal of hepatology.

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Riccardo Lencioni, Angelo Luca, J. Bruix, 2016, Journal of hepatology.

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

S. Friedman, J. Llovet, A. Villanueva, 2017, Gastroenterology.

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

J. Bruix, E. Christensen, J. Llovet, 2002, Gut.

Hepatocellular carcinoma

G. Gores, J. Zucman‐Rossi, M. Sherman, 2016, Nature Reviews Disease Primers.

Immunotherapies for hepatocellular carcinoma

V. Mazzaferro, J. Llovet, A. Zhu, 2021, Nature Reviews Clinical Oncology.

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

S. Friedman, J. Llovet, D. Sia, 2021, Hepatology.

Role of fructose-sorbitol malabsorption in the irritable bowel syndrome

J. Llovet, M. Gassull, F. Fernández-Bañares, 1991 .

Sugar malabsorption in functional bowel disease: clinical implications.

J. Llovet, E. Cabré, M. Gassull, 1993, The American journal of gastroenterology.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

M. Kudo, P. Galle, G. Gerken, 2019, The Lancet. Oncology.

Lin28 Enhances Tumorigenesis and is Associated With Advanced Human Malignancies

John T. Powers, T. Golub, M. Meyerson, 2009, Nature Genetics.

Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock

J. Llovet, I. Ojanguren, E. Cabré, 1996, Hepatology.

Bacterial translocation incirrhotic rats. Itsrole in thedevelopment ofspontaneous bacterial peritonitis

J. Llovet, M. Gassull, M. Jiménez, 1994 .

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

C. Porta, V. Mazzaferro, J. Marrero, 2012, Journal of hepatology.

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

J. Llovet, A. Villanueva, V. Hernández-Gea, 2013, Nature Reviews Gastroenterology &Hepatology.

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.

E. Bini, M. Sherman, J. Llovet, 2007, Journal of hepatology.

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology

M. Kudo, P. Galle, J. Llovet, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

J. Llovet, X. Forns, M. Navasa, 2004, Hepatology.

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

J. Llovet, X. Forns, M. Navasa, 1994, Hepatology.

MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation

Carmen Ayuso, J. Bruix, J. Llovet, 2003, Hepatology.

Targeted therapies for hepatocellular carcinoma.

J. Llovet, A. Villanueva, 2011, Gastroenterology.

Cancer gene discovery in hepatocellular carcinoma.

Derek Y. Chiang, L. Zender, J. Llovet, 2010, Journal of hepatology.

Pivotal role of mTOR signaling in hepatocellular carcinoma.

Derek Y. Chiang, M. Meyerson, V. Mazzaferro, 2008, Gastroenterology.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

A. Subramanian, S. Yamada, Bin Zhang, 2016, Cancer cell.

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.

S. Cairo, M. Buendia, J. Llovet, 2020, Journal of hepatology.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

K. Ross, S. Ramaswamy, Kwok-Kin Wong, 2014, Nature.

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

J. Llovet, Y. Hoshida, S. Nakagawa, 2016, Gut.

DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes

S. Imbeaud, J. Zucman‐Rossi, E. Letouzé, 2021, Hepatology.

Induction of hepatocellular carcinoma by in vivo gene targeting

Pei-Rong Wang, D. Russell, J. Llovet, 2012, Proceedings of the National Academy of Sciences.

Intratumoral heterogeneity and clonal evolution in liver cancer

E. Schadt, R. Sebra, G. Stolovitzky, 2020, Nature Communications.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era

J. Llovet, R. Finn, A. Villanueva, 2015, Nature Reviews Clinical Oncology.

A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma

Derek Y. Chiang, S. Lowe, D. Largaespada, 2009, Nature Biotechnology.

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

V. Mazzaferro, I. Salaverria, L. Bassaganyas, 2020, Clinical Cancer Research.

β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma.

M. Merad, A. Kamphorst, J. Llovet, 2019, Cancer discovery.

Images in hepatology. Intrahepatic bleeding due to undifferentiated (embryonal) hepatic sarcoma.

J. Llovet, A. D. de Lacy, Y. Suárez, 2000, Journal of hepatology.

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

S. Friedman, J. Llovet, S. Toffanin, 2013, Gastroenterology.

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

T. Pawlik, G. Gores, P. Galle, 2014, Journal of hepatology.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Riccardo Lencioni, Barnett S Kramer, Jayant Talwalkar, 2008, Journal of the National Cancer Institute.

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.

T. Pawlik, G. Castellano, L. Bassaganyas, 2020, Journal of hepatology.

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

J. Llovet, Clara Alsinet, Y. Hoshida, 2015, Gut.

1-12-2018 Beta-Catenin Cleavage Enhances Transcriptional Activation

Linheng Li, Q. She, J. Llovet, 2019 .

Beta-catenin cleavage enhances transcriptional activation

Linheng Li, Q. She, J. Llovet, 2018, Scientific Reports.

Impact of intra‐individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma

J. Llovet, A. Villanueva, 2012, Hepatology.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

I. Amit, T. Luedde, M. Ebert, 2021, Nature.

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression.

Derek Y. Chiang, N. Mukhopadhyay, P. Fisher, 2009, The Journal of clinical investigation.

New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers

J. Llovet, Clara Alsinet, Y. Hoshida, 2010, Clinical Cancer Research.

New Strategies Strategies in Hepatocellular Carcinoma : R omic Prognostic Markers

J. Llovet, Clara Alsinet, Y. Hoshida, 2010 .

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

L. Bassaganyas, J. Llovet, M. Vila-Casadesús, 2020, eLife.

CNApp: quantification of genomic copy number alterations in cancer and integrative analysis to unravel clinical implications

L. Bassaganyas, J. Llovet, M. Vila-Casadesús, 2018 .

Hepatocellular carcinoma

A. Burroughs, J. Bruix, J. Llovet, 2003, The Lancet.

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

Derek Y. Chiang, T. Golub, V. Mazzaferro, 2011, Gastroenterology.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

S. Friedman, J. Llovet, J. Martignetti, 2008, Gastroenterology.

A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis

S. Friedman, J. Sninsky, J. Llovet, 2011, Hepatology.

Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer

R. Sebra, G. Stolovitzky, C. Cordon-Cardo, 2021, Gut.

Unannotated small RNA clusters in circulating extracellular vesicles detect early stage liver cancer

R. Sebra, A. Tewari, G. Stolovitzky, 2020, bioRxiv.

Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

P. Schirmacher, J. Llovet, B. Sangro, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemoembolization for hepatocellular carcinoma.

J. Bruix, J. Llovet, M. Sala, 2004, Gastroenterology.

Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma

J. Llovet, M. Ahsen, S. Thung, 2021, PLoS genetics.

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.

J. Bruix, J. Llovet, G. Meinhardt, 2017, Journal of hepatology.

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

J. Bruix, J. Llovet, C Brú, 1999, Seminars in liver disease.

Molecular Targeting in Hepatocellular Carcinoma

J. Llovet, J. Schwartz, 2008 .

Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma

J. Bruix, J. Llovet, 2000, Hepatology.

Molecular targeted therapies in hepatocellular carcinoma

J. Bruix, J. Llovet, Jordi Bruix, 2008, Hepatology.

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers.

J. Llovet, J. Martignetti, S. Finkelstein, 2008, Journal of hepatology.

Genomics and signaling pathways in hepatocellular carcinoma.

Derek Y. Chiang, S. Friedman, J. Llovet, 2007, Seminars in liver disease.

Pathogenesis of hepatocellular carcinoma and molecular therapies

Derek Y. Chiang, J. Llovet, A. Villanueva, 2009, Current opinion in gastroenterology.

CCR1 and CCR5 promote hepatic fibrosis in mice.

R. Schwabe, D. Brenner, J. Llovet, 2009, The Journal of clinical investigation.

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.

J. Bruix, M. Teufel, J. Llovet, 2019, Gastroenterology.

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

M. Esteller, V. Mazzaferro, S. Friedman, 2017, Gastroenterology.

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma

J. Zucman‐Rossi, M. Kudo, V. Paradis, 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection

S. Friedman, J. Llovet, Y. Hoshida, 2015, Gut.

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

M. Kudo, S. Kaneko, J. Llovet, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

P. Schirmacher, S. Friedman, P. Boffetta, 2021, Journal of hepatology.

Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.

V. Mazzaferro, J. Llovet, Y. Hoshida, 2015, Journal of hepatology.

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

S. Gabriel, T. Golub, Supriya Gupta, 2013, Gastroenterology.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Jian-Bing Fan, V. Mazzaferro, S. Friedman, 2011, Journal of hepatology.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

M. Makuuchi, V. Mazzaferro, M. Kudo, 2015, The Lancet. Oncology.

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

R. Lencioni, T. de Baère, J. Llovet, 2021, Nature Reviews Gastroenterology & Hepatology.

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

J. Marrero, M. Kudo, P. Galle, 2020, Hepatology.

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

J. Llovet, V. Hernández-Gea, 2014, Clinical Cancer Research.

Cabozantinib: An evolving therapy for hepatocellular carcinoma.

J. Llovet, R. Kelley, A. El-Khoueiry, 2021, Cancer treatment reviews.

Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence.

J. Llovet, E. Cabré, M. Gassull, 1998, Journal of hepatology.

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma

M. Mahajan, S. Friedman, J. Llovet, 2018, Oncogene.

Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma.

J. Llovet, Clara Alsinet, A. Villanueva, 2012, Journal of hepatology.

hemoembolization for Hepatocellular Carcinoma

J. Llovet, M. Sala, 2022 .

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

M. Kudo, P. Galle, J. Llovet, 2020, Liver international : official journal of the International Association for the Study of the Liver.

mRECIST for HCC: Performance and novel refinements.

R. Lencioni, J. Llovet, 2020, Journal of hepatology.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

J. Llovet, A. Zhu, J. Avruch, 2015, Cell reports.

Integration of genomic information in the clinical management of HCC.

J. Llovet, R. Pinyol, A. Moeini, 2014, Best practice & research. Clinical gastroenterology.

Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.

J. Llovet, X. Forns, S. Ampurdanés, 1996, Gut.

High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV‐1b–related cirrhosis

J. Bruix, J. Llovet, X. Forns, 2001, Hepatology.

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

S. Imbeaud, J. Zucman‐Rossi, P. Laurent-Puig, 2013, Gastroenterology.

Symptomatic eosinophilic granuloma of the spine: report of two cases and review of the literature.

J. Llovet, A. Moreno, E. Galitó, 1984, Orthopedics.

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

J. Bruix, J. Llovet, A. Forner, 2012, Journal of hepatology.

Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials.

J. Llovet, P. Newell, A. Villanueva, 2008, Journal of hepatology.

Chemoembolization for intermediate HCC: is there proof of survival benefit?

J. Bruix, J. Llovet, A. Forner, 2012, Journal of hepatology.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

M. Esteller, V. Mazzaferro, L. Bassaganyas, 2019, British Journal of Cancer.

Resection of hepatocellular cancer ≤2 cm: Results from two Western centers

L. Mariani, V. Mazzaferro, J. Llovet, 2013, Hepatology.

Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials

J. Bruix, J. Llovet, A. Castells, 1999, Hepatology.

Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma

J. Gallon, J. Llovet, L. Terracciano, 2021, Molecular oncology.

IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.

M. Esteller, L. Zender, J. Llovet, 2016, Gastroenterology.

TITLE : IGF 2 is up-regulated by epigenetic mechanisms in hepatocellular 1 carcinoma and is an actionable oncogene in experimental models

M. Esteller, L. Zender, J. Llovet, 2016 .

Approaching focal liver lesions.

J. Llovet, F. Pons, 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Derek Y. Chiang, V. Mazzaferro, S. Friedman, 2009, Journal of hepatology.

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

E. Schadt, V. Mazzaferro, C. Cordon-Cardo, 2015, Nature Communications.

Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma

Jordi Rimola, Carmen Ayuso, J. Bruix, 2009, Cancer.

Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?

R. Lencioni, J. Llovet, 2005, Journal of hepatology.

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

J. Bruix, J. Llovet, G. Meinhardt, 2012, Clinical Cancer Research.

Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis

L. Mariani, V. Mazzaferro, J. Llovet, 2006, Hepatology.

International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.

M. Ronot, V. Vilgrain, J. Llovet, 2023, Journal of hepatology.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

M. Mahajan, S. Friedman, Xintong Chen, 2014, Gut.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Schirmacher, J. Llovet, B. Sangro, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Nicolas Stransky, V. Mazzaferro, J. Llovet, 2019, Cancer discovery.

New molecular therapies for hepatocellular carcinoma.

J. Llovet, S. Torrecilla, 2015, Clinics and research in hepatology and gastroenterology.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

V. Mazzaferro, M. Teufel, J. Llovet, 2018, Clinical Cancer Research.

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

R. Sachidanandam, R. Bronson, Xintong Chen, 2014, Cancer cell.

Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease

L. Schmidt, P. Pinto, J. Llovet, 2010 .

Gene expression profiles in hepatocellular carcinoma: not yet there.

E. Wurmbach, J. Llovet, 2004, Journal of hepatology.

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

P. Galle, Ruifeng Xu, J. Llovet, 2022, Annals of Oncology.

Craniopharyngioma of the third ventricle.

J. Llovet, J. Solé-Llenas, R. Rovira, 1983, Neurochirurgia.

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Ke Hao, J. Llovet, Zhongyang Zhang, 2017, Journal of hepatology.

Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma.

V. Mazzaferro, J. Llovet, F. Miró-Mur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

J. Bruix, J. Llovet, C. Ayuso, 2000, Hepatology.

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

M. Kudo, J. Llovet, D. Madoff, 2022, CardioVascular and Interventional Radiology.

HCC-CCA: Hepatocellular cholangiocarcinoma HCC: Hepatocellular Carcinoma iCCA: Intrahepatic Cholangiocarcinoma WHO: World Health Organization CLC: Cholangiolocellular Carcinoma TGF-beta: Transforming Growth Factor, Beta 1 TERT: Telomerase Reverse Transcriptase KRAS: Kirsten Rat Sarcoma Viral Oncogen

Ke Hao, J. Llovet, Zhongyang Zhang, 2017 .

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

M. Juan, B. Mellado, J. Llovet, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Liver cancer: Approaching a personalized care.

G. Gores, V. Mazzaferro, J. Bruix, 2015, Journal of hepatology.

Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study

R. Baños, A. Sureda, I. Salaverria, 2019, European Journal of Nutrition.

Liver transplantation for small hepatocellular carcinoma: The tumor‐node‐metastasis classification does not have prognostic power

J. Bruix, J. Llovet, J. Visa, 1998, Hepatology.

Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib

J. Llovet, A. Villanueva, 2012, Clinical Cancer Research.

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

M. Kudo, P. Galle, G. Brandi, 2020, JHEP reports : innovation in hepatology.

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials

M. Kudo, P. Galle, J. Llovet, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.

R. Bataller, J. Llovet, M. Navasa, 1997, Journal of hepatology.

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR

D. Largaespada, J. Llovet, Clara Alsinet, 2013, Hepatology.

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Derek Y. Chiang, V. Mazzaferro, J. Bruix, 2010, Journal of hepatology.

Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making

J. Zucman‐Rossi, J. Llovet, J. Nault, 2014, Seminars in Liver Disease.

Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps.

J. Llovet, X. Forns, A. Villanueva, 2012, Journal of hepatology.

PlasmaBiomarkersasPredictorsofOutcomeinPatientswith Advanced Hepatocellular Carcinoma

J. Bruix, J. Llovet, G. Meinhardt, 2012 .

Molecular profiling to predict hepatocellular carcinoma outcome

J. Llovet, Y. Hoshida, A. Villanueva, 2009, Expert review of gastroenterology & hepatology.

Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics.

J. Llovet, E. Cabré, M. Gassull, 1993, American Journal of Gastroenterology.

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

S. Thorgeirsson, V. Mazzaferro, S. Friedman, 2007, Journal of hepatology.

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials

M. Kudo, D. Cella, P. Galle, 2020, ESMO Open.

Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.

Dhwanil A. Dalwadi, D. Russell, J. Llovet, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma

J. Bruix, J. Llovet, M. Solé, 2004, Hepatology.

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results

B. Taouli, Xintong Chen, J. Llovet, 2017, European Radiology.

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

S. Friedman, H. El‐Serag, J. Llovet, 2023, Nature Reviews Gastroenterology & Hepatology.

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

V. Mazzaferro, S. Friedman, J. Llovet, 2022, Gut.

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

J. Bruix, J. Llovet, A. Forner, 2021, Medicina Clínica (English Edition).

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH.

J. Bruix, J. Llovet, A. Forner, 2021, Medicina clinica.

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

V. Mazzaferro, P. Galle, J. Llovet, 2021, Gastroenterology.

Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades

S. Friedman, P. Boffetta, J. Llovet, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

J. Llovet, A. Villanueva, P M Lopez, 2006, Alimentary pharmacology & therapeutics.

Natural history and prognostic prediction of patients with hepatocellular carcinoma

J. Bruix, J. Llovet, M. Varela, 2003 .

Prognostic assessment and evaluation of the benefits of treatment.

J. Bruix, J. Llovet, 2002, Journal of clinical gastroenterology.

Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE).

J. Bruix, R. Lencioni, J. Llovet, 2010 .

Combination therapies for advanced hepatocellular carcinoma: biomarkers and unmet needs.

J. Llovet, S. Cappuyns, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B

J. Llovet, A. Villanueva, M. Schwartz, 2021, JHEP reports : innovation in hepatology.

Reply:

V. Mazzaferro, J. Llovet, M. Schwartz, 2013, Hepatology.

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

M. Kudo, S. Kaneko, J. Llovet, 2020 .

A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

M. Kudo, S. Kaneko, J. Llovet, 2019, Annals of Oncology.

Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.

J. Llovet, G. Fattovich, 2006, Journal of hepatology.

Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015]

J. Llovet, R. Finn, A. Villanueva, 2015 .

R‐spondin 2 Drives Liver Tumor Development in a Yes‐Associated Protein‐Dependent Manner

D. Largaespada, J. Llovet, T. Starr, 2019, Hepatology communications.

Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population

A. Sureda, I. Salaverria, M. Stampfer, 2020, European Journal of Nutrition.

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Caroline L. Wilson, Patrick M. Helbling, F. Tacke, 2019, Nature Medicine.

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

M. Esteller, V. Mazzaferro, L. Bassaganyas, 2019, British Journal of Cancer.

Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255].

J. Llovet, B. Sangro, C. Verslype, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Liver cancer: Translating '–omics' results into precision medicine for hepatocellular carcinoma

J. Llovet, D. Sia, 2017, Nature Reviews Gastroenterology &Hepatology.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

M. Ziol, C. Copie-Bergman, S. Imbeaud, 2020, Hepatology.

Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib

V. Mazzaferro, J. Barretina, S. Friedman, 2012, Clinical Cancer Research.

Living donor liver transplantation for early hepatocellular carcinoma: A life‐expectancy and cost‐effectiveness perspective

J. Bruix, J. Llovet, P. Majno, 2001, Hepatology.

Hepatocellular carcinoma: is surveillance cost effective?

J. Bruix, J. Llovet, 2001, Gut.

[Radiofrequency in the treatment of hepatocellular carcinoma].

J. Llovet, C. Brú, R. Vilana, 2001, Gastroenterologia y hepatologia.

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.

M. Mahajan, L. Bassaganyas, Ke Hao, 2017, Journal of hepatology.

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)

J. Bruix, J. Llovet, C. Fondevila, 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).

M. Kudo, P. Galle, J. Llovet, 2018 .

Clinical and molecular classification of hepatocellular carcinoma

J. Llovet, 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT -Fetoprotein, Des- Carboxyprothrombin, and Lectin-Bound -Fetoprotein in Early Hepatocellular Carcinoma

J. Marrero, A. Lok, D. Chia, 2009 .

Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal

J. Llovet, A. Villanueva, S. Roayaie, 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective.

J. Bruix, J. Llovet, P. Majno, 2001, Hepatology.

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

J. Berlin, K. Haustermans, P. Laurent-Puig, 2023, ESMO Open.

Combination TACE and SBRT for Unresectable Single Large HCC: Results from a Prospective Phase II Trial.

K. Rosenzweig, J. Llovet, M. Schwartz, 2022, International journal of radiation oncology, biology, physics.

[Diagnosis and treatment of hepatocellular carcinoma].

M. Buti, J. Bruix, J. Llovet, 2009, Medicina clinica.

HCC ‐ Medical treatment before and after liver transplantation

J. Llovet, 2010 .

How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?

J. Llovet, M. Schwartz, S. Roayaie, 2005, Journal of hepatology.

Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?

J. Llovet, S. Roayaie, 2005, Clinics in liver disease.

Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence‐based decision

J. Bruix, J. Llovet, J. Fuster, 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

J. Bruix, J. Llovet, C. Nicolau, 2006, European Radiology.

Staging systems in hepatocellular carcinoma.

Fernando Pons, J. Llovet, M. Varela, 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

S. Friedman, J. Llovet, S. Toffanin, 2010, Cancer cell.

Hepatocellular carcinoma: Genome-scale metabolic models for hepatocellular carcinoma

J. Llovet, R. Pinyol, 2014, Nature Reviews Gastroenterology &Hepatology.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

C. N. Coleman, X. Wang, P. Gunaratne, 2019, Cancer research.

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

J. Llovet, S. Choo, T. Meyer, 2016 .

Hepatocellular carcinoma.

W. Meyers, J. Llovet, E. Akriviadis, 1998, The British journal of surgery.

Sublethal necroptosis signaling promotes inflammation and liver cancer.

Ivan G. Costa, Jakob Nikolas Kather, T. Luedde, 2023, Immunity.

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

J. Llovet, J. Heimbach, T. Taddei, 2023, Hepatology.

Molecular approaches to treatment of hepatocellular carcinoma.

J. Llovet, Clara Alsinet, A. Lachenmayer, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

TGF-β oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response

M. Esteller, J. Llovet, Y. Jiao, 2017 .

[Adult living donor liver transplantation. Analysis of the first 30 cases].

J. Llovet, X. Forns, C. Fondevila, 2003, Gastroenterologia y hepatologia.

CLINICAL — LIVER A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection

S. Imbeaud, A. Reyniès, J. Llovet, 2013 .

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

J. Bruix, J. Llovet, J. Aponte, 2001 .

994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL

J. Marrero, J. Bruix, P. Galle, 2008 .

Algorithms of diagnosis and options of hepatocellular carcinoma therapy

J. Llovet, A. Forner, 2008 .

miRNA delivery: emerging therapy for hepatocellular carcinoma.

J. Llovet, A. Villanueva, S. Toffanin, 2010, Gastroenterology.

2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES

Derek Y. Chiang, V. Mazzaferro, J. Bruix, 2008 .

Trunk events present minimal intra-and inter-tumoral heterogeneity in hepatocellular carcinoma

M. Mahajan, L. Bassaganyas, Ke Hao, 2017 .

Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation

J. Llovet, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.

J. Llovet, V. Tovar, R. Pinyol, 2014, Journal of hepatology.

Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography

J. Bruix, J. Llovet, J. Ayuso, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL

J. Bruix, J. Llovet, C. Lathia, 2009 .

LIVER FAILURE AND LIVER DISEASE LIVER FAILURE Initial Response to Percutaneous Ablation Predicts Survival in Patients With Hepatocellular Carcinoma

J. Bruix, J. Llovet, M. Solé, 2004 .

Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

X. Wang, P. Gunaratne, E. Jaffee, 2019, Cancer research.

Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis.

R. Bataller, J. Bruix, J. Llovet, 2000, Journal of hepatology.

Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer

F. Setién, M. Esteller, T. Preiss, 2023, Molecular Cancer.

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

J. Llovet, B. Sangro, C. Verslype, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-surgical therapies of hepatocellular carcinoma.

J. Llovet, M. Sala, 2005, European journal of gastroenterology & hepatology.

J. Bruix, J. Llovet, M. Sala, 2005 .

Pulmonary abscess as a complication of transarterial embolization of multinodular hepatocellular carcinoma.

J. Llovet, J. Cubiella, M. Sans, 1997, The American journal of gastroenterology.

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.

J. Llovet, R. Finn, M. Yarchoan, 2023, JAMA oncology.

The influence of activity of the disease in polyunsaturated fatty acid (PUFA) pattern in inflammatory bowel disease (IBD)

J. Llovet, E. Cabré, M. Gassull, 1990 .

Lymphotoxins: new targets for hepatocellular carcinoma.

J. Llovet, A. Villanueva, R. Savić, 2009, Cancer cell.

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

Mary E. Duffy, J. Llovet, E. Guccione, 2023, Nature Cancer.

Diagnosis and Treatment of Hepatocellular Carcinoma

J. Bruix, J. Llovet, A. Forner, 1998 .

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

R. Beroukhim, Jian-Bing Fan, V. Mazzaferro, 2013, Gastroenterology.

Molecular therapies and precision medicine for hepatocellular carcinoma

J. Llovet, R. Finn, D. Sia, 2018, Nature Reviews Clinical Oncology.

Molecular therapies and precision medicine for hepatocellular carcinoma 1

J. Llovet, R. Finn, D. Sia, 2019 .

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

M. Kudo, J. Bruix, J. Llovet, 2017, The Lancet.

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

S. Friedman, J. Llovet, S. Toffanin, 2013, Gastroenterology.

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

J. Zucman‐Rossi, J. Llovet, A. Villanueva, 2015, Gastroenterology.

New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

J. Llovet, C. Montironi, R. Montal, 2019, Clinical liver disease.

DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma

M. Esteller, V. Mazzaferro, S. Imbeaud, 2015, Hepatology.